Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study.
Giorgia MontrucchioGabriele SalesFrancesca RumboloFilippo PalmesinoVito FanelliRosario UrbinoClaudia FilippiniGiulio MengozziLuca BrazziPublished in: PloS one (2021)
In COVID-19 ICU-patients, MR-proADM seems to have constantly higher values in non-survivor patients and predict mortality more precisely than other biomarkers. Repeated MR-proADM measurement may support a rapid and effective decision-making. Further studies are needed to better explain the mechanisms responsible of the increase in MR-proADM in COVID-19 patients.
Keyphrases
- end stage renal disease
- sars cov
- coronavirus disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- contrast enhanced
- magnetic resonance
- intensive care unit
- peritoneal dialysis
- magnetic resonance imaging
- type diabetes
- computed tomography
- coronary artery disease
- patient reported outcomes
- respiratory syndrome coronavirus
- case control